These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 32559622)

  • 1. Investigational pharmacotherapy and immunotherapy of pulmonary arterial hypertension: An update.
    Yang Y; Lin F; Xiao Z; Sun B; Wei Z; Liu B; Xue L; Xiong C
    Biomed Pharmacother; 2020 Sep; 129():110355. PubMed ID: 32559622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Approaches to treat pulmonary arterial hypertension by targeting BMPR2: from cell membrane to nucleus.
    Dunmore BJ; Jones RJ; Toshner MR; Upton PD; Morrell NW
    Cardiovasc Res; 2021 Sep; 117(11):2309-2325. PubMed ID: 33399862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Search for Disease-Modifying Therapies in Pulmonary Hypertension.
    Woodcock CC; Chan SY
    J Cardiovasc Pharmacol Ther; 2019 Jul; 24(4):334-354. PubMed ID: 30773044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New horizons in pulmonary arterial hypertension therapies.
    Galiè N; Ghofrani AH
    Eur Respir Rev; 2013 Dec; 22(130):503-14. PubMed ID: 24293466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current and emerging therapeutic approaches to pulmonary hypertension.
    Bisserier M; Pradhan N; Hadri L
    Rev Cardiovasc Med; 2020 Jun; 21(2):163-179. PubMed ID: 32706206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological Agents and Potential New Therapies in Pulmonary Arterial Hypertension.
    Santos RT; de Sá Freire Onofre ME; de Assis Fernandes Caldeira D; Klein AB; Rocco PRM; Cruz FF; Silva PL
    Curr Vasc Pharmacol; 2024; 22(3):155-170. PubMed ID: 38115617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulmonary arterial hypertension in the elderly: Clinical perspectives.
    Rothbard N; Agrawal A; Fischer C; Talwar A; Sahni S
    Cardiol J; 2020; 27(2):184-193. PubMed ID: 30155860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment Discontinuation or Interruption in Pulmonary Arterial Hypertension.
    Narechania S; Torbic H; Tonelli AR
    J Cardiovasc Pharmacol Ther; 2020 Mar; 25(2):131-141. PubMed ID: 31594400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension.
    Lang IM; Gaine SP
    Eur Respir Rev; 2015 Dec; 24(138):630-41. PubMed ID: 26621977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pulmonary arterial hypertension specific therapy: The old and the new.
    Zolty R
    Pharmacol Ther; 2020 Oct; 214():107576. PubMed ID: 32417272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-Induced Pulmonary Arterial Hypertension: Mechanisms and Clinical Management.
    Correale M; Tricarico L; Grazioli D; Formica ES; Petrucci R; Persichella P; Di Biase M; Brunetti ND
    Cardiovasc Drugs Ther; 2019 Dec; 33(6):725-738. PubMed ID: 31811420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current status of pulmonary arterial hypertension in Korea.
    Jang AY; Chung WJ
    Korean J Intern Med; 2019 Jul; 34(4):696-707. PubMed ID: 31272141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy of Endothelin-1 Receptor Type A for Pulmonary Arterial Hypertension.
    Dai Y; Chen X; Song X; Chen X; Ma W; Lin J; Wu H; Hu X; Zhou Y; Zhang H; Liao Y; Qiu Z; Zhou Z
    J Am Coll Cardiol; 2019 May; 73(20):2567-2580. PubMed ID: 31118151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow?
    Seferian A; Simonneau G
    Eur Respir Rev; 2013 Sep; 22(129):217-26. PubMed ID: 23997048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beet Juice as Nutraceutical Remedy for Alleviating Pulmonary Arterial Hypertension: Searching for Optimal Treatment Timing and Nitrate Dose.
    Xi L
    Am J Hypertens; 2019 Jan; 32(2):135-138. PubMed ID: 30500880
    [No Abstract]   [Full Text] [Related]  

  • 16. Characteristics and risk factors for pulmonary arterial hypertension associated with primary Sjögren's syndrome: 15 new cases from a single center.
    Zhang N; Zhao Y; Wang H; Sun W; Chen M; Fan Q; Yang Z; Wei W
    Int J Rheum Dis; 2019 Sep; 22(9):1775-1781. PubMed ID: 31368254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical management of riociguat in patients with pulmonary arterial hypertension.
    Halank M; Tausche K; Grünig E; Ewert R; Preston IR
    Ther Adv Respir Dis; 2019; 13():1753466619868938. PubMed ID: 31438774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Future perspectives in pulmonary arterial hypertension.
    Simonneau G; Hoeper MM; McLaughlin V; Rubin L; Galiè N
    Eur Respir Rev; 2016 Dec; 25(142):381-389. PubMed ID: 27903660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxidative and nitrosative signalling in pulmonary arterial hypertension - Implications for development of novel therapies.
    Hansen T; Galougahi KK; Celermajer D; Rasko N; Tang O; Bubb KJ; Figtree G
    Pharmacol Ther; 2016 Sep; 165():50-62. PubMed ID: 27216365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: where do we stand?
    Correale M; Ferraretti A; Monaco I; Grazioli D; Di Biase M; Brunetti ND
    Vasc Health Risk Manag; 2018; 14():253-264. PubMed ID: 30323613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.